Walvax Biotechnology Co., Ltd. (SHE:300142)

Walvax Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	2,538	3,764	4,365	3,873	3,443	1,962
Short-Term Investments	308.17	-	-	-	-	-
Cash & Short-Term Investments	2,846	3,764	4,365	3,873	3,443	1,962
Cash Growth	-14.64%	-13.77%	12.68%	12.49%	75.54%	-17.62%
Accounts Receivable	2,366	2,410	3,101	3,577	2,481	2,004
Other Receivables	59.21	58.8	114.18	416.13	774.86	304.77
Receivables	2,426	2,468	3,215	3,993	3,255	2,308
Inventory	622.76	752.59	1,035	995.81	873.59	483.56
Other Current Assets	832.96	82.22	119.21	86.25	107.94	26.77
Total Current Assets	6,728	7,067	8,733	8,948	7,680	4,780
Property, Plant & Equipment	4,022	4,079	3,768	3,161	2,604	1,590
Long-Term Investments	1,399	1,638	1,057	1,292	1,491	1,605
Goodwill	33.66	33.66	33.66	33.66	33.66	33.66
Other Intangible Assets	889.87	1,035	1,086	1,167	434.98	271.68
Long-Term Accounts Receivable	3.53	7.27	-	-	-	-
Long-Term Deferred Tax Assets	103	104.56	103.44	124.84	168.01	138.55
Long-Term Deferred Charges	545.71	513.86	473.48	309.38	1,022	890
Other Long-Term Assets	278.4	246.62	333.54	300.2	240.63	329.41
Total Assets	14,003	14,724	15,589	15,336	13,674	9,638
Accounts Payable	1,692	1,568	1,805	1,836	1,258	607.79
Accrued Expenses	171.79	549.81	722.05	1,145	754.71	497.41
Short-Term Debt	-	-	320.27	97.18	310	40
Current Portion of Long-Term Debt	18.92	38.98	8.79	-	-	-
Current Portion of Leases	11.6	7.85	21.88	23.35	4.6	-
Current Income Taxes Payable	13.67	-	14.13	19.47	2.03	68.54
Current Unearned Revenue	33.4	106.18	160.47	192.96	35.29	9.68
Other Current Liabilities	447	99.4	151.25	194.15	870.61	198.55
Total Current Liabilities	2,388	2,370	3,204	3,509	3,235	1,422
Long-Term Debt	428.83	433.34	434.9	314.24	-	-
Long-Term Leases	22.17	11.77	20.6	27.74	1.06	-
Long-Term Unearned Revenue	262.31	278.44	423.33	404.53	344.3	256.18
Long-Term Deferred Tax Liabilities	53.96	55.91	68.71	90.94	94.56	112.27
Other Long-Term Liabilities	80.84	67	42.08	-	-	-
Total Liabilities	3,236	3,216	4,194	4,346	3,675	1,790
Common Stock	1,599	1,599	1,607	1,607	1,601	1,546
Additional Paid-In Capital	4,549	4,549	4,900	4,965	4,772	3,262
Retained Earnings	3,137	3,110	2,984	2,580	1,895	1,546
Treasury Stock	-	-	-358.63	-286.42	-	-
Comprehensive Income & Other	211.23	171.28	217.18	217.18	216.33	190.88
Total Common Equity	9,497	9,430	9,349	9,084	8,484	6,545
Minority Interest	1,270	2,078	2,046	1,906	1,515	1,303
Shareholders' Equity	10,766	11,508	11,395	10,990	9,999	7,848
Total Liabilities & Equity	14,003	14,724	15,589	15,336	13,674	9,638
Total Debt	481.52	491.94	806.42	462.51	315.67	40
Net Cash (Debt)	2,365	3,272	3,558	3,411	3,128	1,922
Net Cash Growth	-8.53%	-8.05%	4.31%	9.06%	62.77%	-19.30%
Net Cash Per Share	1.49	2.05	2.22	2.13	1.99	1.23
Filing Date Shares Outstanding	1,599	1,599	1,599	1,601	1,601	1,546
Total Common Shares Outstanding	1,599	1,599	1,599	1,601	1,601	1,546
Working Capital	4,340	4,697	5,529	5,440	4,445	3,358
Book Value Per Share	5.94	5.90	5.85	5.67	5.30	4.23
Tangible Book Value	8,573	8,361	8,230	7,883	8,016	6,239
Tangible Book Value Per Share	5.36	5.23	5.15	4.92	5.01	4.04
Buildings	953.95	953.95	948.5	767.91	541.68	487.84
Machinery	2,213	2,196	2,093	1,580	1,235	930.76
Construction In Progress	2,159	2,114	1,645	1,509	1,527	762.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.